GS
CYTK icon

GTS Securities’s Cytokinetics CYTK Stock Holding History

GTS Securities’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-35,500
Closed -$1.87M – 1916
2024
Q3 		$1.87M Buy
35,500
+16,700
+89% +$931K ﹤0.01% 1612
2024
Q2 		$1.02M Sell
18,800
-196,200
-91% -$11.8M ﹤0.01% 2032
2024
Q1 		$15.1M Sell
215,000
-70,500
-25% -$5.45M 0.03% 349
2023
Q4 		$23.8M Buy
285,500
+275,300
+2,699% +$9.97M 0.04% 285
2023
Q3 		$300K Buy
+10,200
New +$340K ﹤0.01% 3062

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GTS Securities's CYTK Position: Q2 2026 in Review

GTS Securities sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 3,206 shares — an estimated $211K sold.

GTS Securities first reported a position in CYTK in Q3 2023 and held it in 3 quarters. The position peaked at $9.76M in Q4 2023. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • GTS Securities reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
  • GTS Securities sold 3,206 Cytokinetics shares in Q2 2026, an estimated $211K.
  • GTS Securities first reported a position in Cytokinetics in Q3 2023 and held it in 3 quarters.
  • GTS Securities's Cytokinetics position peaked at $9.76M in Q4 2023.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.